Sanofi India Q2 FY27 Results: Standalone Net Profit ₹117 Crore on Total Income of ₹497 Crore

Summary

Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

Net profit grew faster than total income. Net profit rose 53.6% to ₹117 crore while total income rose 3.5% to ₹497 crore, and profit before tax rose 54.2% to ₹158 crore.

Revenue from operations rose 3.4% to ₹492 crore, while other income of ₹6 crore grew 12.2%. Other income is 1.2% of total income this quarter and 3.5% of profit before tax of ₹157.70 crore. The company's press release attributes part of the profit growth to a one-off reversal of provisions; the filing does not give the size of that reversal.

Tax expense rose 55.9% to ₹41 crore, so the effective tax rate was 26.0% of profit before tax this quarter, against about 25.7% a year earlier. Net profit margin widened to 23.47% from 15.82%, a rise of 7.65 percentage points.

Nine-month revenue from operations was ₹14,017 million, or about ₹1,401.7 crore, against ₹14,176 million a year earlier. Nine-month total income was ₹1,417.8 crore and profit for the period ₹302.8 crore, with basic EPS of ₹131.48.

Inference

The Board declared an interim dividend of ₹75 per share for FY 2026, with 5 Nov 2026 as the record date. The filing does not state the total payout.

The filing does not say what the one-off reversal of provisions amounted to or whether it will recur.

Reference: Original filing (PDF)